CHC – The Cancer & Hematology Centers


Name of this trial: ASC2ESCALATE What type of cancer is this for? CML (Chronic Myeloid Leukemia) Who is this trial for? Men and women with chronic myeloid leukemia without T315I mutation who have had one prior ATP-binding site TKI (tyrosine kinase inhibitors) that was stopped because it stopped working or the side effects were too